JP2024016014A5 - - Google Patents

Download PDF

Info

Publication number
JP2024016014A5
JP2024016014A5 JP2023145779A JP2023145779A JP2024016014A5 JP 2024016014 A5 JP2024016014 A5 JP 2024016014A5 JP 2023145779 A JP2023145779 A JP 2023145779A JP 2023145779 A JP2023145779 A JP 2023145779A JP 2024016014 A5 JP2024016014 A5 JP 2024016014A5
Authority
JP
Japan
Prior art keywords
invention described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023145779A
Other languages
English (en)
Japanese (ja)
Other versions
JP7756130B2 (ja
JP2024016014A (ja
Filing date
Publication date
Priority claimed from JP2023513172A external-priority patent/JP7349046B2/ja
Application filed filed Critical
Publication of JP2024016014A publication Critical patent/JP2024016014A/ja
Publication of JP2024016014A5 publication Critical patent/JP2024016014A5/ja
Application granted granted Critical
Publication of JP7756130B2 publication Critical patent/JP7756130B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023145779A 2020-08-24 2023-09-08 Sarm1の阻害剤 Active JP7756130B2 (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202063069408P 2020-08-24 2020-08-24
US63/069,408 2020-08-24
US202163142398P 2021-01-27 2021-01-27
US63/142,398 2021-01-27
JP2023513172A JP7349046B2 (ja) 2020-08-24 2021-08-23 Sarm1の阻害剤
PCT/US2021/047093 WO2022046606A1 (en) 2020-08-24 2021-08-23 Inhibitors of sarm1

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2023513172A Division JP7349046B2 (ja) 2020-08-24 2021-08-23 Sarm1の阻害剤

Publications (3)

Publication Number Publication Date
JP2024016014A JP2024016014A (ja) 2024-02-06
JP2024016014A5 true JP2024016014A5 (enExample) 2024-08-30
JP7756130B2 JP7756130B2 (ja) 2025-10-17

Family

ID=77775005

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023513172A Active JP7349046B2 (ja) 2020-08-24 2021-08-23 Sarm1の阻害剤
JP2023145779A Active JP7756130B2 (ja) 2020-08-24 2023-09-08 Sarm1の阻害剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2023513172A Active JP7349046B2 (ja) 2020-08-24 2021-08-23 Sarm1の阻害剤

Country Status (18)

Country Link
US (2) US12043613B2 (enExample)
EP (1) EP4200293A1 (enExample)
JP (2) JP7349046B2 (enExample)
KR (1) KR20230057396A (enExample)
AU (2) AU2021333558C1 (enExample)
BR (1) BR112023002575A2 (enExample)
CA (1) CA3189181A1 (enExample)
CL (1) CL2023000525A1 (enExample)
CO (1) CO2023001975A2 (enExample)
CR (1) CR20230113A (enExample)
DO (1) DOP2023000038A (enExample)
EC (1) ECSP23012981A (enExample)
IL (1) IL300586A (enExample)
MX (1) MX2023002256A (enExample)
PE (1) PE20230737A1 (enExample)
TW (2) TW202334117A (enExample)
WO (1) WO2022046606A1 (enExample)
ZA (1) ZA202301801B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3897670A4 (en) 2018-12-19 2022-09-07 Disarm Therapeutics, Inc. MRSA1 INHIBITORS IN COMBINATION WITH NEUROPROTECTIVE AGENTS
WO2022031736A1 (en) * 2020-08-04 2022-02-10 Nura Bio, Inc. Substituted pyridine derivatives as sarm1 inhibitors
EP4214197A1 (en) 2020-09-16 2023-07-26 Nura Bio, Inc. Substituted pyridine derivatives as sarm1 inhibitors
KR20240041987A (ko) 2021-07-28 2024-04-01 누라 바이오, 인크. Sarm1 억제제로서 치환된 피리딘 유도체
US20240102018A1 (en) * 2022-07-21 2024-03-28 Amylyx Pharmaceuticals, Inc. Oligonucleotide compositions and methods thereof
EP4634156A1 (en) * 2022-12-15 2025-10-22 Sironax Ltd Sarm1 modulators, preparations, and uses thereof
CN121002009A (zh) 2023-01-24 2025-11-21 达萨玛治疗公司 作为sarm1抑制剂的哒嗪类物
TW202509019A (zh) * 2023-04-27 2025-03-01 香港商維泰瑞隆(香港)生物科技有限公司 Sarm1調節子、其製劑及用途
CN119219603A (zh) * 2023-06-28 2024-12-31 科辉智药(深圳)新药研究中心有限公司 Sarm1酶活性抑制剂及其用途
WO2025045746A1 (en) * 2023-08-25 2025-03-06 F. Hoffmann-La Roche Ag Pyrazole derivatives as sarm1 inhibitors useful for the treatment of neurodegenerative disorders
WO2025049184A1 (en) 2023-08-25 2025-03-06 Eli Lilly And Company (s)-3-((6-fluoropyridin-3-yl)methyl)-1-(5-(pyridin-4-yl)-4h-1,2,4-triazol-3-yl)piperidin-2-one benzenesulfonate
WO2025076017A1 (en) * 2023-10-05 2025-04-10 Genentech, Inc. Carbamates for use as sarm1 inhibitors
WO2025076088A1 (en) * 2023-10-05 2025-04-10 Genentech, Inc. Lactams for use as sarm1 inhibitors
WO2025157895A1 (en) 2024-01-25 2025-07-31 UCB Biopharma SRL Pyrrolidinone derivatives

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6436966B1 (en) 1997-10-27 2002-08-20 Takeda Chemical Ind., Ltd. Adenosine A3 receptor antagonists
US6787555B2 (en) 2001-04-30 2004-09-07 The Procter & Gamble Company Triazole compounds useful in treating diseases associated with unwanted cytokine activity
EP1558607B1 (en) 2002-10-30 2010-05-05 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
EP1581222A2 (en) 2003-01-02 2005-10-05 Millennium Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR INHIBITING TGF-&bgr;
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
US7585881B2 (en) 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
WO2005105780A2 (en) 2004-04-28 2005-11-10 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
WO2006065946A1 (en) 2004-12-16 2006-06-22 Vertex Pharmaceuticals Incorporated Pyrid-2-ones useful as inhibitors of tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases
ES2396251T3 (es) 2006-06-28 2013-02-20 Aska Pharmaceutical Co., Ltd. Derivado de piridilisoxazol
WO2008034600A1 (en) 2006-09-21 2008-03-27 Novartis Ag Pyrrole derivatives useful for the treatment of cytokine-mediated diseases
US20100298286A1 (en) 2007-12-20 2010-11-25 Novartis Ag Organic Compounds
PE20091523A1 (es) 2007-12-20 2009-10-29 Novartis Ag Derivados de tiazol como inhibidores de la enzima fosfatidilinositol 3-cinasa (pi3k)
TW201004941A (en) 2008-07-16 2010-02-01 Wyeth Corp Alpha7 nicotinic acetylcholine receptor inhibitors
US8785468B2 (en) 2009-02-13 2014-07-22 Amgen Inc. Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions
WO2012178022A2 (en) 2011-06-24 2012-12-27 University Of Massachusetts Therapeutic applications targeting sarm1
US9284310B2 (en) 2012-11-03 2016-03-15 Boehringer Ingelheim International Gmbh Inhibitors of cytomegalovirus
EP2934536B1 (en) 2012-12-19 2017-09-27 Merck Sharp & Dohme Corp. FACTOR IXa INHIBITORS
RU2570907C2 (ru) 2013-10-21 2015-12-20 Автономная Некоммерческая Организация "Научно-Исследовательский Центр Биотехнологии Антибиотиков И Других Биологически Активных Веществ "Биоан" Производные 3-ациламинопиридин-2(1h)-она, применимые как ингибиторы серин-треониновой протеинкиназы gsk3b в качестве лекарственных препаратов для лечения диабета ii типа.
EP3076789A4 (en) 2013-12-04 2017-11-22 The Scripps Research Institute Novel compounds as jnk kinase inhibitors
EP4091622A1 (en) 2016-08-16 2022-11-23 Henry Ford Health System Compositions for the treatment of chemotherapy-induced neuropathic pain
CN110545804A (zh) 2016-09-24 2019-12-06 华盛顿大学 Sarm1 nad酶活性抑制剂及其用途
US20180251431A1 (en) 2016-12-09 2018-09-06 Vertex Pharmaceuticals Incorporated 1,3-substituted pyrazole compounds useful for reduction of very long chain fatty acid levels
EP3558986A1 (de) * 2016-12-22 2019-10-30 Bayer CropScience Aktiengesellschaft Substituierte 1,2,4-thiadiazolylpyrrolone und 1,2,4-thiadiazolylhydantoine sowie deren salze und ihre verwendung als herbizide wirkstoffe
CN110392680A (zh) 2016-12-22 2019-10-29 拜耳作物科学股份公司 取代的唑基吡咯酮和唑基乙内酰脲及其盐及其作为除草活性物质的用途
WO2019126733A1 (en) 2017-12-22 2019-06-27 Petra Pharma Corporation Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors
ES3028093T3 (en) 2018-06-07 2025-06-18 Disarm Therapeutics Inc Inhibitors of sarm1
CN112839648B (zh) 2018-06-07 2025-04-04 达萨玛治疗公司 Sarm1抑制剂
WO2019236890A1 (en) * 2018-06-07 2019-12-12 Disarm Therapeutics, Inc. Inhibitors of sarm1
WO2020158762A1 (ja) 2019-01-30 2020-08-06 武田薬品工業株式会社 複素環化合物
WO2020247701A2 (en) 2019-06-06 2020-12-10 Disarm Therapeutics, Inc. Inhibitors of sarm1
JP7319395B2 (ja) 2019-06-14 2023-08-01 ディスアーム セラピューティクス, インコーポレイテッド Sarm1の阻害剤
CA3147858A1 (en) 2019-07-22 2021-01-28 Bayer Aktiengesellschaft 5-amino substituted pyrazoles and triazoles as pest control agents
JP7534390B2 (ja) 2019-09-12 2024-08-14 ディスアーム セラピューティクス, インコーポレイテッド Sarm1の阻害剤
CN114845709B (zh) 2019-11-05 2024-10-01 德米拉公司 用于治疗炎性病症的mrgprx2拮抗剂
BR112022013388A2 (pt) 2020-01-07 2022-09-20 Disarm Therapeutics Inc Inibidores de sarm1
JP7477642B2 (ja) 2020-04-09 2024-05-01 ディスアーム セラピューティクス, インコーポレイテッド Sarm1の阻害剤
CN115916764B (zh) 2020-04-09 2024-09-20 达萨玛治疗公司 作为sarm1抑制剂的吲唑衍生物
WO2022031736A1 (en) 2020-08-04 2022-02-10 Nura Bio, Inc. Substituted pyridine derivatives as sarm1 inhibitors

Similar Documents

Publication Publication Date Title
JP2022068302A5 (enExample)
JP2025120176A5 (enExample)
JP2022028828A5 (enExample)
JP2022025124A5 (enExample)
JP2021185136A5 (enExample)
JP2021169491A5 (enExample)
JP2023116721A5 (enExample)
JP2024059739A5 (enExample)
JP2024016014A5 (enExample)
JP2021028398A5 (enExample)
JP2023022224A5 (enExample)
JP2021038271A5 (enExample)
JP2020127428A5 (enExample)
JP2022060295A5 (enExample)
JP2025160313A5 (enExample)
JP2023100643A5 (enExample)
JP2020120660A5 (enExample)
JP2024112817A5 (enExample)
JP2023011759A5 (enExample)
JP2023085551A5 (enExample)
JP2020171301A5 (enExample)
JP2022022379A5 (enExample)
JP2020141705A5 (enExample)
JP2022122912A5 (enExample)
JP2022172276A5 (enExample)